Addressing female sexual health requires a nuanced understanding of physiological, psychosocial, and psychological determinants. A landmark study published by Lock and colleagues provides critical evidence regarding sexual dysfunction after FGM. Historically, clinicians assumed that surgical alterations or the extent of genital tissue excision directly dictated sexual morbidity. However, contemporary evidence demonstrates that psychological morbidity and traumatic recall exert a far more decisive influence. Female genital mutilation or cutting impacts millions worldwide, including affected populations presenting to gynecology, psychiatry, and general wellness practices. Healthcare practitioners must therefore re-examine conventional assumptions and integrate trauma-informed approaches when managing these complex cases.

Epidemiology and Symptom Patterns of Sexual Dysfunction After FGM

The retrospective cross-sectional investigation evaluated 135 adult women presenting to a specialized academic sexual trauma gynecology clinic between 2014 and 2025. Standardized electronic medical record abstraction captured granular anatomical, psychiatric, and trauma-related metrics. Overall, approximately two-thirds of the cohort reported clinically significant sexual dysfunction. The most frequent presenting symptom was dyspareunia, affecting 45.9% of participants. Furthermore, 28.9% reported diminished sexual pleasure, while 25.9% suffered from reduced libido. In addition, many women experienced overlapping dysfunctions spanning multiple domains. These findings confirm that sexual pain and desire-arousal deficits occur with remarkable frequency among survivors. Consequently, clinicians must proactively screen for these debilitating symptoms during routine gynecologic and primary care visits. Providers should recognize that affected individuals often hesitate to disclose intimate distress spontaneously because of cultural stigma and fear of judgment.

Uncoupling Organ-Specific Genital Anatomy From Sexual Morbidity

For decades, surgical discourse postulated that the severity of sexual dysfunction directly reflected the degree of external genital ablation. Surprisingly, this investigation reveals a striking divergence from that surgical paradigm. Univariate logistic regression analyses demonstrated that absence or attenuation of specific anatomical structures did not correlate significantly with sexual distress. Specifically, loss or scarring of the clitoris, labia minora, or labia majora failed to predict dyspareunia, lost libido, or attenuated pleasure. Even after adjusting for age and anatomical variations, tissue loss did not explain arousal-pleasure deficits. Consequently, clitoral reconstruction may not resolve sexual complaints if underlying trauma remains unaddressed. While structural scarring may contribute to superficial dyspareunia, neurological neuroplasticity and psychophysiological arousal mechanisms appear far more influential. Therefore, clinicians must avoid attributing sexual dysfunction solely to visible anatomical changes when formulating treatment strategies.

The Potent Impact of PTSD and Intact Trauma Recall

Rather than anatomical excision, trauma-related parameters emerged as powerful drivers of sexual health outcomes. Notably, an intact conscious memory of the cutting event significantly increased the odds of experiencing lost libido, demonstrating an odds ratio of 2.82. In addition, post-traumatic stress disorder demonstrated a robust association with low sexual desire, conferring nearly a fourfold increase in risk. Survivors frequently experience intrusive flashbacks, autonomic hyperarousal, and emotional detachment during intimacy. These distress symptoms trigger defensive pelvic floor hypertonicity, compounding both dyspareunia and aversion. Furthermore, in secondary multivariable analyses adjusting for age and genital anatomy, PTSD maintained an independent association with composite arousal-pleasure dysfunction. Thus, the neurobiological sequelae of interpersonal trauma fundamentally alter intimate functioning. Medical providers must evaluate trauma history meticulously, recognizing that unprocessed psychological wounds persistently disrupt sexual well-being.

Depression as a Major Mediator of Arousal and Pleasure Deficits

Depression exhibited the strongest association with impaired intimate functioning across multiple measured endpoints. Specifically, patients diagnosed with clinical depression faced a 2.80-fold higher likelihood of diminished libido and a striking 4.67-fold higher likelihood of complete loss of sexual pleasure. Moreover, after adjusting for patient age and organ-specific genital anatomy, depression remained strongly associated with composite arousal-pleasure dysfunction. Depressive disorders cause pervasive neurochemical dysregulation, affective blunting, and chronic fatigue, which directly undermine sexual desire and hedonic processing. Additionally, feelings of alienation and shame frequently exacerbate depressive distress among survivors. Therefore, addressing mood symptoms represents an essential prerequisite for restoring sexual satisfaction. Gynecologists, psychiatrists, and primary physicians must work collaboratively to screen for affective disorders systematically. Consequently, effective pharmacotherapy, cognitive behavioral interventions, and supportive counseling can substantially improve patient outcomes.

Implementing Trauma-Informed Clinical Evaluation in Practice

Given the intricate interplay between trauma and intimacy, clinicians must adopt compassionate, trauma-informed evaluation protocols. First, practitioners should conduct pelvic examinations with utmost sensitivity, explaining every step beforehand and establishing nonverbal distress cues. Second, clinicians should deliberately screen every survivor for mood disorders, PTSD, and past traumatic memories using validated screening instruments. Providers must also avoid stigmatizing scarred genital anatomy during examination. Furthermore, clinicians should evaluate pelvic floor hypertonicity, which frequently causes chronic dyspareunia secondary to central sensitization. In addition, clinicians must foster open, nonjudgmental communication regarding sexual desire, orgasm, and relationship dynamics. By creating a physically and emotionally safe clinical environment, physicians can demystify symptoms and help patients rebuild bodily autonomy and intimate comfort.

Multidisciplinary Therapeutic Strategies Beyond Surgery

Optimal clinical management requires a coordinated, multimodal therapeutic framework tailored to each survivor's specific presentation. Because anatomical loss does not dictate sexual outcomes, isolated reconstructive surgical interventions should not serve as the primary therapy. Instead, specialized sex therapy, trauma-focused cognitive behavioral therapy, and eye movement desensitization and reprocessing should lead treatment algorithms. Concurrently, specialized pelvic floor physical therapy effectively relieves myofascial pain, hypertonic dyspareunia, and vaginismus. When de-infibulation is anatomically indicated to relieve urinary obstruction or severe introital narrowing, clinicians must combine surgery with comprehensive psychosexual counseling. Pharmacotherapy for underlying depression and anxiety must also be considered judiciously, choosing agents that minimize sexual side effects. Ultimately, cross-disciplinary collaboration among gynecologists, mental health specialists, sexologists, and pelvic physiotherapists ensures holistic, patient-centered healing.

How common is sexual dysfunction among women who have experienced FGM?

Approximately two-thirds of affected women experience sexual dysfunction. In clinical cohorts, dyspareunia is the most common symptom, occurring in nearly 46% of individuals. Additionally, loss of sexual pleasure affects approximately 29%, and diminished libido affects roughly 26% of survivors, reflecting widespread intimate and functional distress.

Does clitoral or labial tissue loss predict sexual dysfunction severity?

Current clinical evidence indicates that tissue loss does not directly predict sexual morbidity. Retrospective analyses show that the absence or attenuation of the clitoris, labia minora, or labia majora does not correlate significantly with dyspareunia, lost libido, or reduced pleasure, disproving long-standing purely anatomical assumptions.

What treatments are most effective for sexual dysfunction after FGM?

Effective management requires multidisciplinary care prioritizing mental health interventions rather than isolated surgical procedures. Clinicians recommend trauma-focused psychotherapy, cognitive behavioral interventions, and specialized pelvic floor physical therapy. These modalities directly address post-traumatic stress disorder, depressive symptoms, and secondary pelvic myofascial hypertonicity that drive intimate distress.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding clinical concerns. Refer to the latest local and national guidelines for clinical practice.

References

1. Lock E et al. Sexual dysfunction after female genital mutilation/cutting: A retrospective cross-sectional study of associations with organ-specific genital anatomy, trauma history, and psychiatric comorbidity. PLoS One. 2026. doi: 10.1371/journal.pone.0356761. PMID: 42752680.
2. World Health Organization. WHO guideline on the prevention of female genital mutilation and clinical management of complications. Geneva: World Health Organization; 2025.
3. Berg RC, Denison E. Does female genital mutilation/cutting impair women's sexual function? A systematic review and meta-analysis. BMJ Open. 2012;2(6):e001878.